In terms of mRNA vaccines for the vaccination, both the former (monovalent) vaccines and the variant-adapted (bivalent) vaccines are suitable. The bivalent mRNA vaccines show good efficacy against serious illness. These vaccines, like the monovalent mRNA vaccines, can top up the immune protection against severe illness in people at especially high risk, at least temporarily. The vaccination provides minimal and short-term protection against infection with mild illness. However, little can be done to prevent transmission of the virus to others.